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Abstract 
TBS seems to be more a reliable determinant of bone quality in patients with this 
condition, since contrary to BMD, it is less susceptible to confounding effects of altered 
hormonal and metabolic parameters.  
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Peak bone mass (PBM) achieved during puberty is a key determinant of bone quality 
in adult women, especially after menopause [1]. PBM is influenced by an array of factors, 
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both extrinsic and intrinsic [2]. Among the latter, particularly important role is played by 
hormonal factors, especially endocrine activity of the ovaries [3]. Hormonal disorders in the 
adolescence result not only in delayed puberty, but also in general disruption of homeostasis, 
including impairment of bone formation. A model example of a hormonal disorder with such 
complex effects is hyperandrogenism, during the course of which relative, and later also 
absolute, deficiency of estrogens is reflected not only by impaired osteogenesis, but also by 
general endocrine disruption and resultant changes in metabolic profile [4]. One consequence 
of excess androgen synthesis is change in the distribution of adipose tissue to android one, 
and a shift in its secretory profile to that typical for visceral fat [5]. Recent evidence suggests 
that these changes may also exert an unfavorable effect on bone mineralization [6]. 
Until recently, either in research or in everyday clinical practice, quality of the bone 
has been assessed on the basis of bone mineral density (BMD) determined densitometrically 
by means of dual energy X-ray absorptiometry (DEXA) [7]. However, results of recent 
studies imply that BMD determined with this method is not an independent predictor of 
osteoporotic fractures; moreover, this parameter can be biased in subjects with extremely low 
or high body weight [8,9]. These findings resulted in development of more accurate marker of 
bone microarchitecture, trabecular bone score (TBS), a measure extracted digitally from 
densitometric images [10]. 
Both our own experiences and results of previous studies imply that BMD in women 
with impaired ovarian function may be modulated by a plethora of hormonal and metabolic 
parameters; this may negatively affect diagnostic accuracy of BMD as a measure of 
subclinical bone depletion and fracture risk. The aim of this study was to determine which 
hormonal and metabolic parameters exert a significant effect on BMD in women with 
hyperandrogenism, and to verify if these factors also influence TBS, a marker of bone 
microarchitecture used increasing in densitometric studies. 
 
Methods 
Patients 
The study, conducted in 2013-2015, included 213 women with hyperandrogenism, treated at 
the Department of Endocrinology, Metabolic and Internal Diseases, Pomeranian Medical 
University in Szczecin (Poland). Age of the study subjects ranged between 19 and 37 years 
(mean 27.08±4.33). The analysis included all patients treated at our clinic during the analyzed 
period, who satisfied the following inclusion criteria: 1) caucasian women not taking 
medicines on a regular basis, without material abnormalities in physical examination, and lack 
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of exclusion criteria. The exclusion criteria were: 1) positive interview for chronic diseases 
and endocrinopathy (polycystic ovary syndrome, diabetes mellitus, thyroid disease, diabetes 
mellitus, hypercortisolemia, gastrointestinal disease, nephropathy and diseases affecting bone 
mineralization). 
Ethics 
Protocol of the study was granted approval from the Local Bioethics Committee at the 
Pomeranian Medical University in Szczecin (decision no. KB-0012/115/15 of 16 November 
2015), and written informed consent was sought from all the study subjects or their legal 
guardians in the case of underage participants. 
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Basic procedures 
Upon history taking and routine clinical examination, anthropometric measurements (body 
weight and body height) were taken in each study subjects, and body mass index (BMI) value 
was calculated. 
 
Laboratory parameters 
The list of determined endocrine parameters included concentrations of androstenedione, 
dehydroepiandrosterone (DHEA), free testosterone and sex hormone-binding globulin 
(SHBG) – used to calculate free androgen index (FAI), 17-hydroxyprogesterone, luteinizing 
hormone (LH), follicle-stimulating hormone (FSH), estradiol, prolactin at the baseline (PRL 
0’) and at 60 min of metoclopramide challenge (PRL 60’), thyroid-stimulating hormone 
(TSH), free triiodothyronine (fT3), free thyroxine (fT4), adrenocorticotropic hormone 
(ACTH), cortisol, as well as the levels of glucose and insulin prior to oral glucose tolerance 
test (75 g, OGTT) and after 60 and 120 min of the test. All parameters were determined using 
conventional methods, electrochemiluminescence immunoassay (ECLIA) for insulin, 
estradiol, LH, FSH, testosterone, SHBG, cortisol, ACTH, TSH, fT3, fT4, PRL, 17-
hydroxyprogesterone and DHEA, immunoenzymatic assay (ELISA) for androstenedione, and 
hexokinase method for glucose. 
 
Determination of bone mineral density and trabecular bone score 
BMD of all the study subjects was determined both for the lumbar spine (L2-L4) and entire 
skeleton by means of dual-energy X-ray absorptiometry (DEXA, GE Lunar Prodigy Advance, 
Madison, WI, USA, with enCORE software version 8.8). The results were expressed as 
absolute values (g/cm
2
) and as z-scores. TBS values of the same lumbar vertebrae were 
determined based on DXA images using dedicated analysis software (TBS I Nsight, version 
2.1.2.0, Medimaps, Mérignac, France). 
 
Determination of adipose tissue distribution and volume 
Quantitative body composition, i.e. overall volume of body fat, volumes of android and 
gynoid fat, were determined by means of DEXA whole body scan (GE Lunar Prodigy 
Advance, Madison, WI, USA) using CoreScan 
TM
 H8801CP and Body Composition software 
packages provided by the manufacturer. 
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Statistical analysis 
Normal distribution of continuous variables was verified with Shapiro-Wilk test and their 
statistical characteristics were presented as arithmetic means, standard deviations (SD), 
medians, lower and upper quartiles. Power and direction of relationships between pairs of 
continuous variables were estimated on the basis of Spearman’s coefficients of rank 
correlation (R). Parameters that showed significant (p≤0.05) or close to statistical significance 
(p≤0.1) associations with dependent variables (TBS or BMD) were included in multiple linear 
regression models to identify independent predictors of these variables. All calculations were 
carried out with Statistica 10 software (StatSoft, USA). 
 
Results 
Detailed characteristics of the study subjects are presented in Table 1. 
TBS correlated positively with both BMD (R=0.334, p<0.001) and BMD z-score 
(R=0.263, p<0.001). Furthermore, statistically significant positive correlations were found 
between TBS, BMI, overall volume of adipose tissue, volume of gynoid fat and TSH 
concentration. In turn, BMD correlated positively with age, BMI, volume of adipose tissue 
overall, volumes of both android and gynoid fat, fasting concentration of insulin, estradiol 
level and FAI. Moreover, an inverse correlation was found between BMD and SHBG 
concentration (Table 2). 
Multivariate regression analysis demonstrated that TBS correlated positively with 
volume of gynoid fat and BMI, and showed an inverse correlation with total adipose tissue 
volume. Resultant regression model was statistically significant but explained only ca. 14% of 
variance within TBS (R
2
=0.138, p<0.0001; Table 3). The only independent predictor of BMD 
identified on multivariate regression analysis was BMI. Also this model, despite statistical 
significance, explained only slightly above 16.5% of variance within the dependent variable 
(R
2
=0.167, p<0.001; Table 4). 
 
Discussion 
This study demonstrated that BMD and TBS in women with hyperandrogenism are 
determined by different factors. BMI turned out to be the only independent predictor of BMD. 
Indeed, results of early studies suggested a positive correlation between body weight and bone 
mineralization, and this association was explained by a stimulatory effect of greater 
mechanical load on osteogenesis [11]. However, further research demonstrated that bone 
mineralization is determined by fat mass, rather than by total body weight or BMI [12]. 
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Further discovery that adipose tissue is not merely a passive lipid reservoir, but disseminated 
endocrine gland with region-specific profiles of secreted substances, provided better insight in 
this phenomenon [13]. According to literature, gynoid fat, i.e. subcutaneous tissue 
accumulated around hips, breasts and thighs, synthesizes primarily pro-osteogenic and anti-
osteolytic factors, such as adiponectin, leptin and aromatase [14-16]. In contrast, visceral 
adipose tissue, and probably also android (abdominal) fat, are sources of compounds that 
promote bone resorption, such as proinflammatory cytokines (TNF-alpha and IL-6) [17,18] 
and cell adhesion molecules (sICAM1 and E-selectin) [19,20]. Our data on independent 
predictors of TBS are consistent with these findings. Multivariate analysis of regression 
demonstrated that TBS in our study subjects correlated with their BMI and gynoid fat volume, 
and showed an inverse correlation with total volume of adipose tissue. The latter observation 
is an indirect proof for an inverse correlation between TBS, visceral and android fat contents. 
Univariate analysis demonstrated, that aside from its independent predictors 
mentioned above, i.e. BMI, total volume of adipose tissue and gynoid fat volume, TBS 
correlated with only one parameter, TSH level. Theoretically, TSH might exert an indirect 
pro-osteogenic effect mediated via triiodothyronine (T3), as higher levels of the latter were 
recently shown to be associated with better qualitative characteristics of the bone [21]. 
However, such mechanism is unlikely, since we neither found a significant correlation 
between fT3 and TBS or BMD, nor THS proved to be an independent predictor of bone 
architecture on multivariate analysis. It cannot be excluded that the positive correlation 
between TSH and TBS was mediated by leptin since in one previous study, this pro-
osteogenic adipokine synthesized in subcutaneous (in particular gynoid) fat was shown to 
correlate positively with TSH level [22]. Under such assumption, women with larger volumes 
of gynoid fat would synthesize more leptin, and the latter would exert independent effects on 
TSH metabolism and bone quality. 
The number of factors that influenced BMD of our study subjects on univariate 
analysis was markedly higher than in the case of TBS. Aside from BMI, adipose tissue 
volume overall, gynoid and android fat volumes, BMD also correlated positively with fasting 
insulin, estradiol level and FAI, and showed an inverse correlation with SHBG concentration. 
None of these factors turned out to be an independent predictor of BMD on multivariate 
analysis, which implies that they were all linked to excess body weight and/or adiposity, 
rather than to bone mineralization. However, a large body of evidence suggests that all these 
parameters may also influence BMD directly. Estrogen deficiency is a well-established risk 
factor for bone loss [23-25]. Skeletal demineralization may also result from preferential 
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binding of androgens by SHBG and lack of their further conversion to estrogens [26-28]; this 
mechanism would explain why BMD in our study subjects correlated inversely with BMD 
and increased with FAI values. Finally, insulin was previously shown to stimulate 
differentiation of osteoblasts, probably via upregulation of osteocalcin [29-31]. 
Taken altogether, these findings imply that TBI may be a more reliable measure of 
bone quality in patients with hyperandrogenism than BMD. First, the results of multivariate 
analysis for TBS are consistent with published data on the biological role of adipose tissue in 
bone metabolism, whereas the results for BMD are quite conflicting. Second, the results of 
univariate analyses imply that contrary to BMD, TBS is less susceptible to confounding 
effects of other hormonal and metabolic parameters that may be substantially altered during 
the course of hyperandrogenism. 
One principal limitation of this study is its retrospective character, due to which we 
were unable to exclude potential effects of additional laboratory parameters, such as leptin. 
Furthermore, our analysis was not adjusted for all potential determinants of bone quality, as 
shown by low R
2
 values for both multivariate models. Other factors with established influence 
on bone properties are diet, physical activity, sunlight exposure and concomitant medications 
[32-35]. Finally, our study did not include a control group. Nevertheless, we hope that due to 
appropriate selection of statistical methodology (analysis of correlation and regression, rather 
than intergroup comparisons) and large sample size, the hereby presented findings are 
reliable; this assumption seems to be supported by their substantial consistency with 
published evidence. 
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Conclusions 
TBS seems to be more a reliable determinant of bone quality in patients with this condition, 
since contrary to BMD, it is less susceptible to confounding effects of altered hormonal and 
metabolic parameters.  
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Table 1. Clinicodemographic characteristics of the study subjects. 
Variable Mean SD Median 
Lower 
quartile 
Upper 
quartile 
Age (years) 27.08 4.33 27.00 24.00 30.00 
BMI (kg/m
2
) 25.60 5.82 23.80 20.90 30.00 
Fat overall (cm
3
) 37.69 8.65 37.50 31.20 44.90 
Android fat (cm
3
) 41.14 12.63 42.70 31.30 51.60 
Female fat (cm
3
) 42.98 7.37 43.00 38.20 48.10 
BMD (g/cm
2
) 1.23 0.13 1.24 1.15 1.32 
z-score 0.23 0.98 0.30 -0.40 1.00 
TBS 1.38 0.09 1.38 1.32 1.43 
Glucose 0' (mg/dl) 86.65 9.72 87.00 81.00 92.00 
Insulin 0' (µIU/ml) 12.61 10.93 9.90 6.72 14.52 
Glucose 60' (mg/dl) 114.43 36.21 112.90 87.20 134.20 
Insulin 60' (µIU/ml) 88.28 72.79 65.78 42.22 106.40 
Glucose 120' (mg/dl) 93.69 28.53 92.00 73.00 109.00 
Insulin 120' (µIU/ml) 58.78 60.80 37.05 24.22 66.20 
Androstenedione (ng/ml) 3.94 1.91 3.60 2.85 4.78 
DHEA (µg/ml) 260.07 125.48 254.00 178.00 325.00 
Testosterone (ng/ml) 0.50 0.22 0.48 0.36 0.62 
SHBG (nmol/l) 56.11 45.98 45.50 28.34 70.70 
FAI 5.29 5.18 3.94 2.07 6.46 
17-hydroxyprogesterone (ng/ml) 1.17 0.65 1.10 0.76 1.47 
LH (mIU/ml) 9.02 7.66 6.93 4.74 11.15 
FSH (mIU/ml) 6.13 5.75 5.57 4.59 6.71 
Estradiol (pg/ml) 69.42 81.71 45.34 32.61 70.49 
PRL 0' (ng/ml) 20.11 24.06 16.65 11.20 22.40 
PRL 60' (ng/ml) 166.18 73.81 157.80 121.70 189.80 
TSH (µIU/ml) 2.40 3.50 1.81 1.31 2.83 
fT3 (pg/ml) 3.05 0.35 2.95 2.80 3.34 
fT4 (ng/dl) 1.44 1.80 1.23 1.12 1.33 
Cortisol (µg/dl) 16.63 6.26 15.75 12.40 20.19 
ACTH (pg/ml) 34.41 47.84 26.49 19.42 38.00 
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Table 2. Spearman’s coefficients of rank correlation (R) between trabecular bone score (TBS) 
and bone mineral density (BMD) in lumbar spine and other clinicodemographic 
characteristics of the study subjects. 
Explanatory variables 
TBS BMD (g/cm
2
) 
R p R p 
Age (years) 0.024 0.728 0.153 0.026 
BMI (kg/m
2
) 0.282 <0.001 0.394 0.000 
Fat overall (cm
3
) 0.175 0.012 0.284 0.000 
Android fat (cm
3
) 0.136 0.061 0.290 0.000 
Female fat (cm
3
) 0.199 0.004 0.208 0.002 
Glucose 0' (mg/dl) 0.017 0.817 0.047 0.509 
Insulin 0' (µIU/ml) -0.010 0.891 0.173 0.016 
Glucose 60' (mg/dl) -0.007 0.926 0.078 0.289 
Insulin 60' (µIU/ml) -0.059 0.432 0.059 0.424 
Glucose 120' (mg/dl) -0.039 0.595 0.064 0.380 
Insulin 120' (µIU/ml) -0.058 0.427 0.058 0.428 
Androstenedione (ng/ml) -0.066 0.341 -0.038 0.585 
DHEA (µg/ml) -0.046 0.509 0.046 0.503 
Testosterone (ng/ml) -0.032 0.648 0.072 0.295 
SHBG (nmol/l) -0.072 0.298 -0.212 0.002 
FAI 0.044 0.534 0.192 0.006 
17-hydroxyprogesterone (ng/ml) -0.020 0.770 0.047 0.492 
LH (mIU/ml) -0.029 0.672 -0.048 0.487 
FSH (mIU/ml) 0.016 0.823 -0.093 0.175 
Estradiol (pg/ml) -0.099 0.154 0.180 0.008 
PRL 0' (ng/ml) -0.043 0.541 0.076 0.267 
PRL 60' (ng/ml) -0.059 0.398 0.054 0.429 
TSH (µIU/ml) 0.157 0.027 -0.065 0.359 
fT3 (pg/ml) -0.147 0.114 -0.014 0.884 
fT4 (ng/dl) 0.054 0.458 0.092 0.205 
Cortisol (µg/dl) 0.084 0.351 0.099 0.263 
ACTH (pg/ml) 0.012 0.893 0.049 0.592 
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Table 3. Determinants of trabecular bone score (TBS) in lumbar spine of women with 
hyperandrogenism – results of multivariate analysis of regression. 
Explanatory 
variable 
b* SE for b* b SE for b p 
BMI (kg/m
2
) 0.447 0.126 0.007 0.002 0.001 
Fat overall (cm
3
) -0.716 0.228 -0.008 0.002 0.002 
Female fat (cm
3
) 0.638 0.174 0.008 0.002 <0.001 
TSH (µIU/ml) 0.034 0.069 0.001 0.002 0.619 
 
Table 4. Determinants of bone mineral density (BMD) in lumbar spine of women with 
hyperandrogenism – results of multivariate analysis of regression. 
Explanatory 
variable 
b* SE for b* b SE for b p 
Age (years) 0.122 0.072 0.003 0.002 0.091 
BMI (kg/m
2
) 0.401 0.132 0.008 0.003 0.003 
Fat overall (cm
3
) -0.086 0.341 -0.001 0.005 0.801 
Android fat (cm
3
) 0.117 0.239 0.001 0.002 0.626 
Female fat (cm
3
) -0.008 0.182 <-0.001 0.003 0.967 
Insulin 0' (µIU/ml) -0.130 0.085 -0.001 0.001 0.127 
SHBG (nmol/l) -0.020 0.080 <-0.001 <0.001 0.804 
FAI -0.070 0.086 -0.002 0.002 0.418 
Estradiol (pg/ml) 0.083 0.070 <0.001 <0.001 0.237 
 
